12 Jan 2026 by admin in UncategorizedComments Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
05 Jan 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
